MBMichael Benatar

Michael Benatar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael Benatar has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Joanne Wuu

    Department of Neurology, Emory University School of Medicine, Atlanta, Georgia

    3 shared publications
  • Achraf A. Makki

    Department of Neurology, Emory University, Atlanta, GA 30322, USA

    2 shared publications
  • Henry Kaminski

    2 shared publications
  • Jerome Kurent

    Medical University of South Carolina; Department of Neurosciences and Medicine; 135 Rutledge Avenue Room 1237, PO Vox 250591 Charleston USA SC 29425-0591

    2 shared publications
  • Limin Peng

    Department of Biostatistics and Bioinformatics, Emory University Rollins School of Public Health, Atlanta, Georgia, USA

    2 shared publications
  • Anthony V Swan

    National Hospital for Neurology and Neurosurgery

    1 shared publication

Latest Publications

  • Open Access

    Impact of presymptomatic genetic testing for familial amyotrophic lateral sclerosis

    by Joanna H. Fanos, Susan Gronka, Joanne Wuu, Christine Stanislaw, Peter M. Andersen, Michael Benatar


  • Preparing for a U.S. National ALS Registry: Lessons from a pilot project in the State of Georgia

    by Michael Benatar, Joanne Wuu, Sharon Usher, Kevin Ward

    Our objective was to investigate the utility of existing data sources for identifying cases of amyotrophic lateral sclerosis (ALS) and related motor neuron diseases (MND) in the State of Georgia. Data were acquired from Medicare, Medicaid, Veterans Administration, Emory Healthcare, community neurologists, the ALS Association, and mortality records for ALS/MND patients residing in Georgia during 2001-2005. A neurologist used abstracted medical records to verify the diagnosis of ALS/MND. The positive predictive value (PPV) of an ICD code for a verified diagnosis of ALS was estimated. Simple 'rules' were developed to improve PPV. Results showed that a total of 2413 unique potential cases were identified in existing data sources. Medical records of 579 cases were available for review; the diagnosis of ALS (or a related MND) was confirmed in 486 (PPV = 84%) cases. Predictive rules, which permitted classification of ∼80% of the chart-reviewed population, improved PPV to 96-98%. In conclusion, existing data sources are useful for identifying cases of ALS/MND; most data sources contribute a substantial number of unique cases. Predictive algorithms may permit correct classification of a large proportion of cases without the need for verification based on medical record review.


  • Pearls: Myasthenia

    by Michael Benatar

    Myasthenia gravis is typically an acquired autoimmune disorder in which antibodies are directed at structural components of the neuromuscular junction, most commonly the nicotinic acetylcholine receptor. The clinical manifestations of skeletal muscle weakness are broad. Patients most often report fatigable muscle weakness. The eyelid levators and extraocular muscles are most commonly affected, resulting in symptoms of ptosis and diplopia. Symptoms may be confined to the eyes (ocular myasthenia) or reflect bulbar, limb, or respiratory muscle weakness (generalized myasthenia). The diagnosis is based on a characteristic history and the finding of fatigable muscle weakness on examination, and may be supported by diagnostic tests such as finding elevated titers of acetylcholine receptor or muscle-specific receptor tyrosine kinase (MuSK) antibodies, a positive Tensilon test, a decremental response on slow repetitive nerve stimulation, and abnormal jitter on single fiber electromyography. This article presents a series of pearls to aid in the clinical and laboratory diagnosis of myasthenia gravis, emphasizing key historical features, common and characteristic findings on examination, and potential pitfalls in the use of ancillary diagnostic studies.


  • Reference data for commonly used sensory and motor nerve conduction studies

    by Michael Benatar, Joanne Wuu, Limin Peng

    Introduction: The goal of this study was to generate reference data for a wide range of sensory and motor nerve conduction studies (NCSs) that are commonly used in routine electrodiagnostic practice. Methods: NCS data were collected from control subjects with a normal neurological examination and no known risk factors for or symptoms to suggest disease of the peripheral nervous system. Thirteen sensory and motor nerves were studied in the upper and lower limbs using standard recording techniques. Quantile regression was used to obtain estimates of the lower (e.g., 5th) percentiles for sensory and motor amplitudes and conduction velocities, as well as estimates of the upper (e.g., 95th) percentiles for distal motor latency and F‐wave latencies. Results: Reference data for sensory and motor amplitudes required adjustment for age; F‐wave latencies required adjustment for gender. Covariate adjustments were not required for other reference data. Data from N = 100 and N = 190 subjects permitted estimation of as low as the 4th and 2nd percentile, respectively, but further increases to N = 296 did not permit estimation of a more extreme percentile. Discussion: Efforts to develop reference data require careful selection of study subjects; sufficient sample size; adjustment for relevant covariates; and appropriate statistical methods for analysis. Reference data that cannot be estimated reliably due to absent potentials or data variability must be interpreted with caution. We present data for a range of clinically applicable reference percentiles, but judgment regarding which is most appropriate for diagnostic purpose awaits empiric evaluation in a disease population. Muscle Nerve 40: 772–794, 2009


  • Developing reference data for nerve conduction studies: An application of quantile regression

    by Limin Peng, Joanne Wuu, Michael Benatar

    Introduction: The interpretation of nerve conduction studies, as with any diagnostic test, requires an ability to differentiate normal from abnormal. To this end there have been many efforts to establish reference or normative data, but they have been hampered by a variety of methodological shortcomings. The goal of this article is to introduce a statistical method known as quantile regression, which we contend is better suited than existing methods to generate reference data, especially when there is a need to adjust for covariates. Methods: Statistical methods previously used for generation of reference data are reviewed. Quantile regression is presented and used to estimate the lower percentiles for response amplitudes of the radial sensory and tibial motor nerves. Results: Using data from 190 subjects, it is possible to estimate as low as the 2nd percentile for the radial nerve. Using data from 99 subjects it is possible to estimate as low as the 4th percentile for the tibial nerve. Percentile estimation for both nerves required adjustment for age, but no other covariates. Discussion: Quantile regression is well suited to the estimation of extreme percentiles, the very percentiles that are most relevant to reference data. It is also less dependent on data distribution and permits covariate adjustment, even for continuous variables such as age, which are clinically important determinants of reference data for nerve conduction studies. We recommend the use of quantile regression for future studies of reference data. Muscle Nerve 40: 763–771, 2009


  • Treatment for familial amyotrophic lateral sclerosis/motor neuron disease

    by Michael Benatar, Jerome Kurent, Dan H Moore

    Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a rare neurodegenerative disease. Approximately 5% to 7% of ALS/MND patients report a family history of a similarly affected relative. Superoxide dismutase-1 gene mutations are the cause in about 20% of familial cases. In those with non-familial (sporadic) ALS/MND the cause is unknown. Also unknown is whether patients with familial and sporadic ALS/MND respond differently to treatment. To systematically review the literature and to answer the specific question: 'Is there a difference in the response to treatment between patients with sporadic and familial forms of ALS?' In May 2006 we searched the Cochrane Neuromuscular Disease Group Trials Register, MEDLINE (January 1966 to May 2006) and EMBASE (January 1980 to May 2006) for randomized controlled trials (RCTs). Two review authors read the titles and abstracts of all articles and reviewed the full text of all possibly relevant articles. We scanned references of all included trials to identify additional relevant articles. For all trials eligible for inclusion we contacted the authors to request the necessary raw data. Studies had to meet two criteria: (a) randomized controlled study design, and (b) inclusion of patients with both familial and sporadic ALS/MND. We attempted to contact authors of all trials that met inclusion criteria. We obtained data regarding ALS/MND type (sporadic versus familial), treatment assignment (active versus placebo), survival and ALS Functional Rating Scale scores for four large RCTs that included 822 sporadic and 41 familial ALS patients. We could not obtain data from 25 potentially eligible studies (17 trial authors could not be contacted and eight were unwilling to provide data). There was no statistical evidence for a different response to treatment in patients with familial ALS/MND compared to those with sporadic ALS/MND. The pooled estimate of the hazard ratio for the interaction term (treatment x familial ALS) suggested a more beneficial response with respect to survival among patients with familial ALS/MND, but the result was not statistically significant. Estimates of the rate of decline on the ALS Functional Rating Scale also suggested a slightly better response to treatment among those with familial ALS/MND, but the result was not statistically significant. Future RCTs should document whether patients with familial ALS/MND are included and the presence or absence of a mutation in the superoxide dismutase-1 gene amongst those with familial ALS/MND.


  • Diagnostic Accuracy of Thoracic Paraspinal Electromyography in Amyotrophic Lateral Sclerosis

    by Achraf A. Makki, Michael Benatar

    The goal of this study was to estimate the accuracy of thoracic paraspinal (T-PSP) electromyography (EMG), performed at the time of initial evaluation, for the subsequent clinical diagnosis of amyotrophic lateral sclerosis (ALS). Medical records from a consecutive series of patients referred for suspected ALS were abstracted. Those in whom T-PSP EMG was not performed or for whom follow-up was not available were excluded. The study population included 64 patients. T-PSP EMG was abnormal in 28 (44%) study patients, 26 (93%) of whom were subsequently diagnosed with ALS. T-PSP EMG showed neither fibrillation potentials nor positive sharp waves in 36 (56%) patients, 9 (25%) of whom later developed ALS. The sensitivity of T-PSP for the diagnosis of ALS was 0.74 and the specificity was 0.93. The likelihood ratio positive was 10.5 and the likelihood ratio negative was 0.28. These results suggest that T-PSP EMG is very useful for "ruling in" the diagnosis of ALS, but less useful as a screening test for "ruling out" the diagnosis. Because T-PSP EMG is used clinically in an effort to confirm the diagnosis (and not as a screening test), these results suggest that T-PSP EMG is an extremely useful adjunct for the diagnosis of ALS.


  • The electromyographic diagnosis of amyotrophic lateral sclerosis: Does the evidence support the El Escorial criteria?

    by Achraf A. Makki, Michael Benatar

    The aim of this retrospective cohort study was to examine the accuracy of the El Escorial electromyographic criteria for the diagnosis of amyotrophic lateral sclerosis (ALS). Based on a consecutive series of 73 patients with suspected ALS, the sensitivity of electromyography (EMG) ranged from 0.2 in the cranial segment to 0.74 in the thoracic segment. Specificity was highest (0.92–1.0) in the cranial and thoracic segments. Using receiver operating characteristic (ROC) curve analysis to examine the effect of varying the number of abnormal segments required for the diagnosis, we found an overall accuracy of 0.90 and 0.87 if one or two abnormal segments, respectively, were required. The best combination of sensitivity and specificity was achieved by requiring EMG changes in two segments with abnormalities in a single muscle in the cranial and thoracic segments, but abnormalities in two muscles in the cervical and lumbosacral regions. These findings lend support to the EMG criteria proposed at El Escorial. Muscle Nerve, 2007